Meeting
2016 ASCO Annual Meeting
TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.
Authors
Pol M. Specenier
Antwerp University Hospital, Edegem, Belgium
Pol M. Specenier , Eva Remenar , J. Buter , Dirk L. Schrijvers , Lisa F. Licitra , Ahmad Awada , Paul M. Clement , Catherine Fortpied , Ravi Karra Gurunath , Jan Baptist Vermorken
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT00646659
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6076)
DOI
10.1200/JCO.2016.34.15_suppl.6076
Abstract #
6076
Poster Bd #
398
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
First Author: Andreas Dietz
Poster
2019 ASCO Annual Meeting
Randomized phase II study with or without induction chemotherapy combined with accelerated high dose radiotherapy and cetuximab in locally advanced unresectable HPV positive squamous cell carcinoma of the head and neck.
First Author: Signe Friesland